New Delhi, Jan. 12 -- In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anti-cancer drug nivolumab in India, citing public interest.

The court modified a July 2025 single-judge order that had restrained the launch on the plea of innovator and patent holder E.R. Squibb & Sons LLC, which sells the drug under the brand Opdivo.

A bench of justices C. Hari Shankar and Om Prakash Shukla permitted continued sales, noting that Squibb's patent is due to expire on 2 May 2026, and directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can be compensated in case it ultimately succeeds in the pate...